Unknown

Dataset Information

0

Exogenous NADPH exerts a positive inotropic effect and enhances energy metabolism via SIRT3 in pathological cardiac hypertrophy and heart failure.


ABSTRACT:

Background

Therapies are urgently required to ameliorate pathological cardiac hypertrophy and enhance cardiac function in heart failure. Our preliminary experiments have demonstrated that exogenous NADPH exhibits a positive inotropic effect on isolated heart. This study aims to investigate the positive inotropic effects of NADPH in pathological cardiac hypertrophy and heart failure, as well as the underlying mechanisms involved.

Methods

Endogenous plasma NADPH contents were determined in patients with chronic heart failure and control adults. The positive inotropic effects of NADPH were investigated in isolated toad heart or rat heart. The effects of NADPH were investigated in isoproterenol (ISO)-induced cardiac hypertrophy or transverse aortic constriction (TAC)-induced heart failure. The underlying mechanisms of NADPH were studied using SIRT3 knockout mice, echocardiography, Western blotting, transmission electron microscopy, and immunoprecipitation.

Findings

The endogenous NADPH content in the blood of patients and animals with pathological cardiac hypertrophy or heart failure was significantly reduced compared with age-sex matched control subjects. Exogenous NADPH showed positive inotropic effects on the isolated normal and failing hearts, while antagonism of ATP receptor partially abolished the positive inotropic effect of NADPH. Exogenous NADPH administration significantly reduced heart weight indices, and improved cardiac function in the mice with pathological cardiac hypertrophy or heart failure. NADPH increased SIRT3 expression and activity, deacetylated target proteins, improved mitochondrial function and facilitated ATP production in the hypertrophic myocardium. Importantly, inhibition of SIRT3 abolished the positive inotropic effect of NADPH, and the anti-heart failure effect of NADPH was significantly reduced in the SIRT3 Knockout mice.

Interpretation

Exogenous NADPH shows positive inotropic effect and improves energy metabolism via SIRT3 in pathological cardiac hypertrophy and heart failure. NADPH thus may be one of the potential candidates for the treatment of pathological cardiac hypertrophy or heart failure.

Funding

This work was supported by grants from the National Natural Science Foundation of China (No. 81973315, 82173811, 81730092), Natural Science Foundation of Jiangsu Higher Education (20KJA310008), Jiangsu Key Laboratory of Neuropsychiatric Diseases (BM2013003) and the Priority Academic Program Development of the Jiangsu Higher Education Institutes (PAPD).

SUBMITTER: Qian K 

PROVIDER: S-EPMC10663691 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications

Exogenous NADPH exerts a positive inotropic effect and enhances energy metabolism via SIRT3 in pathological cardiac hypertrophy and heart failure.

Qian Ke K   Tang Jie J   Ling Yue-Juan YJ   Zhou Ming M   Yan Xin-Xin XX   Xie Yu Y   Zhu Lu-Jia LJ   Nirmala Koju K   Sun Kang-Yun KY   Qin Zheng-Hong ZH   Sheng Rui R  

EBioMedicine 20231109


<h4>Background</h4>Therapies are urgently required to ameliorate pathological cardiac hypertrophy and enhance cardiac function in heart failure. Our preliminary experiments have demonstrated that exogenous NADPH exhibits a positive inotropic effect on isolated heart. This study aims to investigate the positive inotropic effects of NADPH in pathological cardiac hypertrophy and heart failure, as well as the underlying mechanisms involved.<h4>Methods</h4>Endogenous plasma NADPH contents were determ  ...[more]

Similar Datasets

| S-EPMC10861652 | biostudies-literature
| S-EPMC6009970 | biostudies-literature
| S-EPMC7093179 | biostudies-literature
| S-EPMC4487898 | biostudies-literature
2018-07-30 | PXD010165 | Pride
2010-03-08 | GSE7487 | GEO
2015-11-01 | E-GEOD-73597 | biostudies-arrayexpress
| S-EPMC11785575 | biostudies-literature
| S-EPMC9240797 | biostudies-literature
2025-01-29 | GSE203083 | GEO